<DOC>
	<DOCNO>NCT02468687</DOCNO>
	<brief_summary>The study evaluate N-methyl-pyrrolidone ( NMP ) safely administer human dos , induce measurable immunological anti-tumour effect patient myeloma resistant intolerant lenalidomide bortezomib .</brief_summary>
	<brief_title>NMP Relapsed / Refractory Myeloma</brief_title>
	<detailed_description>N‐Methyl‐2‐pyrrolidone ( NMP ) small molecule acetyl‐lysine mimetic compound potent ( low micromolar range ) immunomodulatory direct anti‐myeloma activity attributable BETbromodomain inhibition high concentration . NMP nontoxic , stable already use solvent biomedical application . It subject numerous toxicity study human demonstrate adverse effect . The study propose empiric start dose 50mg daily , 50 % see healthy volunteer observable toxicity . Dose escalation follow rule base accelerate trial design order minimise number patient treat sub‐therapeutic dos minimise length study . During accelerated dose‐escalation phase , one patient enter per cohort dose escalation increment 100 % , 6 dose escalation two dose de‐escalation levels.The accelerated phase end one patient experience DLT first cycle treatment total two patient experienced moderate toxicity first cycle treatment regardless dose level ; recent patient treat high dose level first cycle . If 1 patient experience DLT first cycle dose level , cohort expand total 6 patient treat dose level . The maximum tolerated dose ( MTD ) study define high dose incidence DLT le 33 % .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Histologically confirm diagnosis plasma cell myeloma define WHO 2008 criterion 2 . Measurable disease define least one : serum M protein ≥5g/L urine M protein ≥ 200mg/24hrs involved serum free light chain ≥ 100mg/L measurable ( image discretion investigator ) soft tissue plasmacytoma 3 . Relapsed , refractory intolerant bortezomib lenalidomide Definitions : refractory least 4 week therapy administer , less partial response IMWG criterion relapse previous response ( PR great ) therapy , subsequent disease progression define development bone marrow dysfunction ( fall Hb 20g/L platelet count &lt; 100 x 109/L ) due increase bone marrow plasmacytosis OR new lytic bone lesion OR increase serum M protein 5g/L OR absolute increase involve serum free light chain &gt; 250mg/L intolerant : grade 2 high toxicity unresponsive dose adjustment 4 . Prior autologous stem cell transplant , unless ineligible transplant discretion investigator . 5. age ≥18 year 6 . ECOG performance status &lt; 2 7 . The following value within 7 day commence NMP ( blood transfusion prior study entry permit ) Haemoglobin &gt; 80g/L Absolute neutrophil count &gt; 1.0 x 109/L Platelet count ≥ 25 x 109/L Creatinine clearance &gt; 30ml/min ( Cockcroft/Gault ) Bilirubin ≤ 3x upper limit normal ( ULN ) ALT ≤ 3 x ULN Left ventricular ejection fraction ( LVEF ) ≥45 % ( gated cardiac blood pool scan echocardiography ) 9 . Life expectancy &gt; 3 month 10 . Able give write informed consent 11 . In opinion investigator , willing able comply require study procedures 12 . Able take oral medication ( malabsorptive condition ) 1 . Pregnant breastfeed female patient 2 . Female child bear potential unwilling unable use two method contraception 3 . Received chemotherapy , immunotherapy biological therapy within two week enrolment . Prednisolone 20mg per day permit non‐myeloma indication . 4 . Patients history another malignancy within 2 year baseline visit , exclude treat non‐melanotic skin cancer in‐situ carcinoma . 5 . Patients know CNS involvement unless previously treat well controlled period ≥3 month AND require use steroid . 6 . Uncontrolled intercurrent illness include , limited : Active uncontrolled infection , include active HIV viral ( A , B C ) hepatitis . NOTE : Patients control infection antibiotic antifungal therapy eligible i.e . patient afebrile least 72 hour haemodynamically stable . Impaired cardiac function , include follow : Myocardial infarction within previous 3 month prior start study Symptomatic congestive heart failure ( New York Heart Association Class III , IV ) Symptomatic coronary artery disease Cardiac arrhythmia control medication Clinically significant rest bradycardia ( &lt; 50 beat per minute ) Long QT syndrome know family history long QT syndrome QTc &gt; 450 msec baseline ECG ( use QTcF formula ) . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient re‐screened QTc Inability monitor QT/QTc interval ECG Other clinically significant uncontrolled heart disease ( e.g . unstable angina uncontrolled hypertension ) Impaired hepatic renal impairment ( see inclusion criterion ) Uncontrolled diarrhoea , nausea vomit 7. concomitant exposure another investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Relapsed/Refractory</keyword>
</DOC>